These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 16501039

  • 1. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study.
    Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC.
    Hum Reprod; 2006 Jun; 21(6):1400-7. PubMed ID: 16501039
    [Abstract] [Full Text] [Related]

  • 2. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
    Yilmaz M, Karakoç A, Törüner FB, Cakir N, Tiras B, Ayvaz G, Arslan M.
    Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907
    [Abstract] [Full Text] [Related]

  • 3. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
    Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE.
    Fertil Steril; 2004 Oct; 82(4):893-902. PubMed ID: 15482765
    [Abstract] [Full Text] [Related]

  • 4. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome.
    Belli SH, Graffigna MN, Oneto A, Otero P, Schurman L, Levalle OA.
    Fertil Steril; 2004 Mar; 81(3):624-9. PubMed ID: 15037412
    [Abstract] [Full Text] [Related]

  • 5. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance.
    Lemay A, Dodin S, Turcot L, Déchêne F, Forest JC.
    Hum Reprod; 2006 Jan; 21(1):121-8. PubMed ID: 16199428
    [Abstract] [Full Text] [Related]

  • 6. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
    Shi Y, Guo M, Yan J, Sun W, Zhang X, Geng L, Xu L, Chen Z.
    Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
    [Abstract] [Full Text] [Related]

  • 7. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome.
    Cataldo NA, Abbasi F, McLaughlin TL, Basina M, Fechner PY, Giudice LC, Reaven GM.
    Hum Reprod; 2006 Jan; 21(1):109-20. PubMed ID: 16155076
    [Abstract] [Full Text] [Related]

  • 8. Effects of oral fat and glucose tolerance test on serum lipid profile, apolipoprotein, and CRP concentration, and insulin resistance in patients with polycystic ovary syndrome.
    Bahceci M, Aydemir M, Tuzcu A.
    Fertil Steril; 2007 Jun; 87(6):1363-8. PubMed ID: 17362944
    [Abstract] [Full Text] [Related]

  • 9. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
    Mitkov M, Pehlivanov B, Terzieva D.
    Eur J Obstet Gynecol Reprod Biol; 2006 May 01; 126(1):93-8. PubMed ID: 16360262
    [Abstract] [Full Text] [Related]

  • 10. Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance.
    Hung YJ, Hsieh CH, Pei D, Kuo SW, Lee JT, Wu LY, He CT, Lee CH, Fan SC, Sheu WH.
    Clin Endocrinol (Oxf); 2005 Jan 01; 62(1):85-91. PubMed ID: 15638875
    [Abstract] [Full Text] [Related]

  • 11. [Exploration of the classification of polycystic ovarian syndrome].
    Lin JF, Li X, Zhu MW.
    Zhonghua Fu Chan Ke Za Zhi; 2006 Oct 01; 41(10):684-8. PubMed ID: 17199924
    [Abstract] [Full Text] [Related]

  • 12. Patterns of hormonal response to the GnRH agonist leuprolide in brothers of women with polycystic ovary syndrome: a pilot study.
    Petermann TS, Cartes A, Maliqueo M, Vantman D, Gutiérrez C, Toloza H, Echiburú B, Recabarren SE.
    Hum Reprod; 2004 Dec 01; 19(12):2742-7. PubMed ID: 15358722
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Plasma visfatin levels in normal weight women with polycystic ovary syndrome.
    Panidis D, Farmakiotis D, Rousso D, Katsikis I, Delkos D, Piouka A, Gerou S, Diamanti-Kandarakis E.
    Eur J Intern Med; 2008 Oct 01; 19(6):406-12. PubMed ID: 18848173
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D, Farmakiotis D, Rousso D, Kourtis A, Katsikis I, Krassas G.
    Fertil Steril; 2008 Apr 01; 89(4):899-906. PubMed ID: 17980364
    [Abstract] [Full Text] [Related]

  • 18. Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study.
    Penna IA, Canella PR, Reis RM, Silva de Sá MF, Ferriani RA.
    Hum Reprod; 2005 Sep 01; 20(9):2396-401. PubMed ID: 16006454
    [Abstract] [Full Text] [Related]

  • 19. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
    Diamanti-Kandarakis E, Katsikis I, Piperi C, Alexandraki K, Panidis D.
    Clin Endocrinol (Oxf); 2007 Jan 01; 66(1):103-9. PubMed ID: 17201808
    [Abstract] [Full Text] [Related]

  • 20. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H, Tanir HM, Yildiz Z.
    Arch Gynecol Obstet; 2006 Jul 01; 274(4):227-32. PubMed ID: 16691383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.